scholarly journals Utility of HIV-1 DNA genotype in determining antiretroviral resistance in patients with low or undetectable HIV RNA viral loads

2018 ◽  
Vol 73 (11) ◽  
pp. 3129-3136 ◽  
Author(s):  
Narjis Boukli ◽  
Anders Boyd ◽  
Marianne Collot ◽  
Jean-Luc Meynard ◽  
Pierre-Marie Girard ◽  
...  
Keyword(s):  
Viral Loads ◽  
Hiv Rna ◽  
Antiretroviral Resistance ◽  
Hiv 1

scholarly journals HIV-1 Tropism Evolution after Short-Term Maraviroc Monotherapy in HIV-1-Infected Patients

2012 ◽  
Vol 56 (7) ◽  
pp. 3981-3983 ◽  
Author(s):  
Alejandro Gonzalez-Serna ◽  
María Concepción Romero-Sánchez ◽  
Sara Ferrando-Martinez ◽  
Miguel Genebat ◽  
Francesc Vidal ◽  
...  
Keyword(s):  
Virological Response ◽  
Ccr5 Antagonist ◽  
Clinical Test ◽  
Short Term ◽  
Viral Tropism ◽  
Viral Loads ◽  
Hiv Rna ◽  
Hiv 1 ◽  
Shed Light

ABSTRACTWe analyzed the evolution of viral tropism after 8 days of maraviroc monotherapy, i.e., we used the maraviroc clinical test (MCT), in 21 patients with and 14 without virological response to the drug (MCT+and MCT−patients, respectively). No increases in CXCR4 inferred viral loads (X4IVLs) were observed in MCT+patients, while X4IVLs increased only in MCT−patients, with X4IVLs of >2 log10HIV RNA copies/ml. These results shed light on the evolution of viral tropism under a CCR5 antagonistin vivo.

scholarly journals Safety, Pharmacokinetics, and Efficacy of (+/−)-β-2′,3′-Dideoxy-5-Fluoro-3′-Thiacytidine with Efavirenz and Stavudine in Antiretroviral-Naïve Human Immunodeficiency Virus-Infected Patients

2005 ◽  
Vol 49 (7) ◽  
pp. 2828-2833 ◽  
Author(s):  
C. Herzmann ◽  
K. Arastèh ◽  
R. L. Murphy ◽  
H. Schulbin ◽  
P. Kreckel ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Racemic Mixture ◽  
Pharmacokinetic Parameters ◽  
Viral Loads ◽  
Hiv Rna ◽  
Immunodeficiency Virus ◽  
Additional Therapy ◽  
Hiv 1 ◽  
Rna Levels

ABSTRACT Racivir [RCV; (+/−)-β-2′,3′-dideoxy-5-fluoro-3′-thiacytidine], a 50:50 racemic mixture of the two β nucleoside enantiomers, is currently in development for the treatment of human immunodeficiency virus type 1 (HIV-1) infections. RCV was administered once a day orally for 14 days at doses of 200, 400, or 600 mg in combination with stavudine and efavirenz to HIV-1-infected treatment-naïve male volunteers in a phase Ib/IIa study. Six volunteers at each dose were monitored for a total of 35 days for tolerance, pharmacokinetics, and plasma HIV RNA levels. RCV in combination with stavudine and efavirenz was well tolerated at all doses tested. Pharmacokinetic parameters were dose proportional, and the maximum concentration of drug in serum at all doses exceeded the 90% effective concentration for wild-type HIV-1. Viral loads dropped as expected in all dosage groups, with mean reductions from 1.13 to 1.42 log10 by day 4 and 2.02 to 2.43 log10 by day 14. HIV RNA levels remained suppressed for more than 2 weeks in the absence of any additional therapy, with mean viral loads ranging from 2.1 to 2.6 log10 below baseline through day 28. By day 35, HIV RNA levels began to increase but still remained >1 log10 below baseline levels.

Accumulated Mutations Cause Significant Fitness Losses and are Associated with Decreased Viral Loads During Early HIV-1 Infection

2019 ◽  
Author(s):  
Chu Wang ◽  
Donglai Liu ◽  
Tao Zuo ◽  
Bhavna Hora ◽  
Fangping Cai ◽  
...  
Keyword(s):  
Viral Loads ◽  
Hiv 1

P21 Prevalence of antiretroviral resistance mutations in treatment-naive HIV-1-infected patients in South London

HIV Medicine ◽  
2000 ◽  
Vol 1 (3) ◽  
pp. 179-179
Author(s):  
Am Geretti ◽  
M Smith ◽  
M Donati ◽  
P Easterbrook ◽  
M Zuckerman
Keyword(s):  
Resistance Mutations ◽  
Antiretroviral Resistance ◽  
Treatment Naïve ◽  
Hiv 1

scholarly journals Nationwide Study of Drug Resistance Mutations in HIV-1 Infected Individuals under Antiretroviral Therapy in Brazil

2021 ◽  
Vol 22 (10) ◽  
pp. 5304
Author(s):  
Ana Santos-Pereira ◽  
Vera Triunfante ◽  
Pedro M. M. Araújo ◽  
Joana Martins ◽  
Helena Soares ◽  
...  
Keyword(s):  
Drug Resistance ◽  
People Living With Hiv ◽  
Resistance Mutations ◽  
Subtype C ◽  
Viral Loads ◽  
Drug Resistance Mutations ◽  
Subtype B ◽  
Low Prevalence ◽  
Living With Hiv ◽  
Hiv 1

The success of antiretroviral treatment (ART) is threatened by the emergence of drug resistance mutations (DRM). Since Brazil presents the largest number of people living with HIV (PLWH) in South America we aimed at understanding the dynamics of DRM in this country. We analyzed a total of 20,226 HIV-1 sequences collected from PLWH undergoing ART between 2008–2017. Results show a mild decline of DRM over the years but an increase of the K65R reverse transcriptase mutation from 2.23% to 12.11%. This increase gradually occurred following alterations in the ART regimens replacing zidovudine (AZT) with tenofovir (TDF). PLWH harboring the K65R had significantly higher viral loads than those without this mutation (p < 0.001). Among the two most prevalent HIV-1 subtypes (B and C) there was a significant (p < 0.001) association of K65R with subtype C (11.26%) when compared with subtype B (9.27%). Nonetheless, evidence for K65R transmission in Brazil was found both for C and B subtypes. Additionally, artificial neural network-based immunoinformatic predictions suggest that K65R could enhance viral recognition by HLA-B27 that has relatively low prevalence in the Brazilian population. Overall, the results suggest that tenofovir-based regimens need to be carefully monitored particularly in settings with subtype C and specific HLA profiles.

CD4+ T cell count, HIV-1 viral loads and demographic variables of newly identified patients with HIV infection in Wuhan, China

2013 ◽  
Vol 85 (10) ◽  
pp. 1687-1691 ◽  
Author(s):  
Man-Qing Liu ◽  
Li Tang ◽  
Wen-Hua Kong ◽  
Ze-Rong Zhu ◽  
Jin-Song Peng ◽  
...  
Keyword(s):  
T Cell ◽  
Hiv Infection ◽  
Cell Count ◽  
Demographic Variables ◽  
Cd4 T Cell ◽  
Viral Loads ◽  
Hiv 1 ◽  
Cd4 T Cell Count

scholarly journals HIV-1 Antiretroviral Resistance

Drugs ◽  
2012 ◽  
Vol 72 (9) ◽  
pp. e1-e25 ◽  
Author(s):  
Michele W. Tang ◽  
Robert W. Shafer
Keyword(s):  
Antiretroviral Resistance ◽  
Hiv 1
Sign in / Sign up

Export Citation Format

Share Document